Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.2.008
Autophagy: When to strike?
Shadi Zahedi1,2, Jean M. Mulcahy Levy1,2,3,*
- 1Department of of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA
- 2Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado, Aurora, USA
- 3Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA
Corresponding Author
Jean M. Mulcahy Levy, Jean.MulcahyLevy@cuanschutz.edu
Received Date: January 11, 2020
Accepted Date: February 06, 2020
Zahedi S, Mulcahy Levy JM. Autophagy: When to strike? J Cancer Immunol. 2020; 2(1): 13-16.
Copyright: © 2020 Zahedi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers
Background: We have recently published SL-BioDP, a web resource for querying, exploration and visualization of potential synthetic lethal targets and possible synergistic drug combinations for 18 cancer types. Methods: From our predictive synthetic lethality model used in SL-BioDP, we inferred TP53 mutation lead to potential synergistic drug combination of Bortezomib and Vorinostat. Here we show, how to extrapolate the drug combination results by combining drug screening data from cancer cell lines and showed the potential synergy of the drug targets, proteasome, and histone deacetylase (HDAC) pathways respectively, for patient survival advantage.
Combination Therapies with Anti-angiogenesis and B7-H3 Blockade in Cancers
Tumor angiogenesis, a hallmark of cancer, is a critical step in the tumorigenesis of solid cancers. The process of tumor angiogenesis is orchestrated by a range of secreted factors, signaling pathways as well as nonendothelial cells.
A New Player in an Old Story: FBXO16 Prevents Breast Cancer Tumorigenesis through Disrupting Cellular Function of Nuclear β-Catenin
β-Catenin is the central modulator of the canonical Wnt signaling pathway. Upon Wnt on state, β-Catenin is translocated to the nucleus and function as a transcription coactivator for several oncogenes. In Wnt off state, β-catenin is mostly localized in the cytoplasm and sequestered by the destruction complex, the negative regulator of β-catenin expression [2,3].
Pregnancy Specific Glycoproteins: A Possible Mediator of Immune Tolerance of Cancers
Cancer immunotherapy relies upon the immune system recognizing and killing cancer cells. Tumors can elude recognition by readapting existing mechanisms of immune control and suppression. Here we explore the hypothesis that cancers repurpose the immune suppression employed during pregnancy to protect the allogeneic fetus. Those mechanisms are reviewed and shown to be employed both in pregnancy and by tumors.
DIS3L2: Unveiling a New Player in Tumorigenesis, with a Key Role in Colorectal Cancer
DIS3L2 is a 3’-5’ exoribonuclease that recognizes and degrades uridylated transcripts in an exosome-independent manner and participates in several RNA degradation pathways, such as the nonsense-mediated mRNA decay, or the surveillance of aberrant structured non-coding RNAs. Although some studies have linked DIS3L2 to tumorigenesis and cancer-related processes, its exact role in the development and progression of cancer